Skip to content
10-K

Annual Report

Petros Pharmaceuticals, Inc. PTPI

0001104659-26-043822

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 15, 2026 42.37M sh
Shares Diluted FY 2025 · Dec 31, 2025 28.07M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 321.04K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$6.73M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$2.6M
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.14M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $1.72M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.87M
Stockholders Equity FY 2025 · Dec 31, 2024 −$7.47M
Stockholders Equity FY 2025 · Dec 31, 2023 $12.07M
Current Liabilities FY 2025 · Dec 31, 2025 $2.29M
Current Liabilities FY 2025 · Dec 31, 2024 $18.03M
Total Liabilities FY 2025 · Dec 31, 2025 $2.29M
Total Liabilities FY 2025 · Dec 31, 2024 $18.1M
Current Assets FY 2025 · Dec 31, 2025 $5.16M
Current Assets FY 2025 · Dec 31, 2024 $7.29M
Total Assets FY 2025 · Dec 31, 2025 $5.16M
Total Assets FY 2025 · Dec 31, 2024 $10.64M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.56
Eps Diluted restated FY 2025 · Dec 31, 2024 −$83.47
Eps Basic FY 2025 · Dec 31, 2025 −$1.56
Eps Basic restated FY 2025 · Dec 31, 2024 −$83.47
Sga Expense FY 2025 · Dec 31, 2025 $4.64M
Sga Expense restated FY 2025 · Dec 31, 2024 $4.63M
Net Income FY 2025 · Dec 31, 2025 $1.91M
Net Income FY 2025 · Dec 31, 2024 −$14.32M
Operating Income FY 2025 · Dec 31, 2025 −$4.64M
Operating Income restated FY 2025 · Dec 31, 2024 −$4.63M